LXEO News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

LX

Mkt Cap

$216.3M

Volume

1.23M

Next Earnings

November 4th

Loading chart

LX

LXEOLexeo Therapeutics, Inc. Common Stock

LXEO

Pay with—

Available Balance0.00

LX

Mkt Cap

$226.6M

Volume

1.23M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Lexeo Therapeutics to Participate in the Chardan Healthcare ConferenceLexeo Therapeutics, a clinical-stage biotech company, announced it will participate in a fireside chat at Chardan's 10th Annual Healthcare Conference on October 20, 2026. The company is focused on developing genetic disease treatments, including LX2006 for Friedreich ataxia and LX2020 for arrhythmogenic cardiomyopathy.GlobeNewswire Inc. · Oct 8, 2026

Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)Lexeo Therapeutics announced that its abstract for LX2006, an AAV-based gene therapy for Friedreich ataxia, has been accepted for oral presentation at the MDS 2026 Congress in Seoul. The presentation will highlight early stabilization or improvement in mFARS scores in LX2006-treated participants compared to propensity-matched controls, along with new subscore analyses. LX2006 has received multiple FDA designations including Breakthrough Therapy and Orphan Drug status.GlobeNewswire Inc. · Oct 1, 2026

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic CardiomyopathyLexeo Therapeutics reported positive interim Phase I/II data for LX2020, an AAV-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy. The therapy demonstrated good tolerability across 10 participants, with 93-162% increases in PKP2 protein expression and stabilization or improvement in arrhythmia burden in the majority of participants. The company plans to complete 12-month data collection by Q4 2026 and engage with regulators in 2026.GlobeNewswire Inc. · Jan 12, 2026

Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene TherapyLexeo Therapeutics announced a research collaboration with Johnson & Johnson to investigate localized cardiac delivery of AAV gene therapy using Impella heart pump technology. The partnership aims to improve the efficacy and safety of gene therapy for genetically mediated cardiovascular diseases by concentrating viral delivery to the heart while reducing required AAV doses.GlobeNewswire Inc. · Jan 8, 2026

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private PlacementLexeo Therapeutics has priced a public offering and private placement, raising approximately $135 million by selling 15,625,000 shares at $8.00 per share and pre-funded warrants to Balyasny Asset Management.GlobeNewswire Inc. · Oct 17, 2025

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia CardiomyopathyLexeo Therapeutics reports positive interim clinical data for LX2006, a gene therapy for Friedreich Ataxia cardiomyopathy, with FDA openness to an accelerated approval pathway and promising results showing cardiac and neurologic improvements.GlobeNewswire Inc. · Oct 7, 2025

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational StudyLexeo Therapeutics announces positive interim data for its gene therapy candidate LX2006 in treating Friedreich ataxia cardiomyopathy, with participants showing clinically significant improvements in cardiac biomarkers and increased frataxin expression. The company plans to initiate a registrational study by early 2026.GlobeNewswire Inc. · Apr 7, 2025

2 Stocks Riding the Biotech Surge With Major Catalysts AheadThe biotechnology sector has experienced significant volatility, with Tonix Pharmaceuticals and Lexeo Therapeutics seeing major stock price surges. These surges were driven by positive regulatory updates and financial results, respectively, indicating potential long-term value for these companies.Investing.com · Mar 26, 2025

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational HighlightsLexeo Therapeutics reported positive interim data from Phase 1/2 studies in Friedreich ataxia cardiomyopathy, showing LX2006 was well-tolerated and demonstrated evidence of sustained treatment effect. The company also initiated formal engagements with the FDA on surrogate endpoints for a registrational study and expects to provide an update by the end of 2024.GlobeNewswire Inc. · Aug 12, 2024

Lexeo Therapeutics Announces Positive Interim Phase 1/2 - GlobeNewswireLexeo Therapeutics announced positive interim data from its Phase 1/2 clinical trial of LX2006, a gene therapy candidate for the treatment of Friedreich ataxia cardiomyopathy. The data showed clinically meaningful improvements in cardiac biomarkers and increased frataxin protein expression in participants.GlobeNewswire Inc. · Jul 15, 2024

to start trading

LX

LXEOLexeo Therapeutics, Inc. Common Stock

LXEO

Pay with—

Available Balance0.00

Your PositionYou don't own any LXEO yet.

Related Tickers

Earnings